CD19-PD1-CAR T cell therapy (Chinese PLA General Hospital)

N/A

Report date: 2024/11/21 20:00:04

Base Information

Drug NameCD19-PD1-CAR T cell therapy (Chinese PLA General Hospital)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsProgrammed cell death protein 1 modulators

TargetsB-lymphocyte antigen CD19Programmed cell death protein 1

Therapy Area/IndicationsLymphoma, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaPending

Originator CompaniesPla General Hospital

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesPla General Hospital

Active IndicationsN/A

Inactive IndicationsLymphoma, B-Cell

Other Information

ATC CodeN/A